Opinion statement
The degree of clinical expression of both obstructive and nonobstructive hypertrophic cardiomyopathy (HCM) is widely variable. Many patients with HCM are asymptomatic or minimally symptomatic. Most patients with mild or moderate HCM respond well to medical therapy, but medical therapy in patients with severe disease is only marginally beneficial. In some instances, medical therapy can even complicate management by producing significant conduction disturbances. Most symptomatic patients with a significant resting outflow tract gradient may respond to atrioventricular sequential electronic pacing. Most of these patients eventually become symptomatic again, however, because of progression of the disease process or other unknown factors. The outcome of myotomy-myectomy depends greatly on the surgeon’s experience with this surgical procedure. In patients with very severe hypertrophy or evidence of left ventricular dilatation and systolic dysfunction, cardiac transplantation should be considered earlier than it would be on the basis of symptoms, functional capacity, and other factors.
Similar content being viewed by others
References and Recommended Reading
Braunwald E: Hypertrophic cardiomyopathy—continued progress. N Engl J Med 1989, 320:800–804.
Goodwin JF, Krikler DM: Arrhythmia as a cause of sudden cardiac death in hypertrophic cardiomyopathy. Lancet 1976, 2:937–940.
Webb-Peploe MM, Croxson RS, Oakley CM, et al.: Cardioselective beta-adrenergic blockade in hypertrophic cardiomyopathy. Postgrad Med J 1971, 47(suppl):93–101.
Louie EK, Edwards LC: Hypertrophic cardiomyopathy. Prog Cardiovasc Dis 1994, 36:275–308.
Fananapazir L, Epstein ND, Curiel RV, et al.: Long-term results of dual chamber (DDD) pacing in obstructive hypertrophic cardiomyopathy: evidence for progressive symptomatic and hemodynamic improvement and reduction in left ventricular hypertrophy. Circulation 1994, 90:2731–2742.
Nishimura RA, Trusty JM, Hayes DL, et al.: Dual-chamber pacing for patients with hypertrophic obstructive cardiomyopathy: a prospective randomized, doubleblind cross-over study. J Am Coll Cardiol 1997, 29:435–441. This important study evaluates the usefulness of DDD electronic pacing, a newer but controversial method of treatment of hypertrophic obstructive cardiomyopathy.
Robbins RC, Stinson EB: Long-term results of left ventricular myotomy and myectomy for obstructive cardiomyopathy. J Thorac Cardiovasc Surg 1996, 111:586–594.
Maron BJ, Shirani J, Poliac LC, et al.: Clinical demographic and pathologic profile of sudden death in 158 young competitive athletes. JAMA 1996, 276:199–204.
McKenna WJ, Oakley CM, Krikler DM, Godwin JF: Improved survival with amiodarone in patients with hypertrophic cardiomyopathy and ventricular tachycardia. Br Heart J 1985, 53:412–416.
McKenna WJ, Camm WJ: Sudden death in hypertrophic cardiomyopathy: assessment of patients at high risk. Circulation 1989, 80:1489–1492.
Maron BJ: Hypertrophic cardiomyopathy. Curr Probl Cardiol 1993, 18:639–651.
Fifer MA, O’Gara PT, McGovern BA, Semigran MJ: Effects of disopyramide on left ventricular diastolic function in hypertrophic cardiomyopathy. Am J Cardiol 1994, 74:405–408.
Duncan WJ, Tyrrell MJ, Bharadwaj BB: Disopyramide as a negative inotrope in obstructive cardiomyopathy in children. Can J Cardiol 1991, 2:81–86.
Criley JM, Siegel RJ: Subaortic stenosis revisited. The importance of the dynamic pressure gradient. Medicine (Baltimore) 1993, 72:412–436.
Schoendube FA, Klues HG, Reith S, et al.: Long-term clinical and echocardiographic follow-up after surgical correction of hypertrophic cardiomyopathy with extended myectomy and reconstruction of the subvalvular mitral apparatus. Circulation 1995, 92(suppl):122–127.
Maron BJ: Hypertrophic cardiomyopathy. Lancet 1997, 350:127–133. This timely review from an expert in the field gives a brief but comprehensive overview of hypertrophic cardiomyopathy.
Winkel E, DiSesa VJ, Costanzo MR: Advances in heart transplantation. Dis Mon 1999, 45:63–87.
Fananapazir L, Epstein SE: Value of electrophysiologic evaluation of patients with hypertrophic cardiomyopathy surviving cardiac arrest. Am J Cardiol 1991, 67:280–286.
Sigwart U: Nonsurgical myocardial reduction for hypertrophic obstructive cardiomyopathy. Lancet 1995, 346:211–216.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Barron, J.T. Hypertrophic cardiomyopathy. Curr Treat Options Cardio Med 1, 277–282 (1999). https://doi.org/10.1007/s11936-999-0044-2
Issue Date:
DOI: https://doi.org/10.1007/s11936-999-0044-2